Biased ligands: pathway validation for novel GPCR therapeutics

Curr Opin Pharmacol. 2014 Jun;16:108-15. doi: 10.1016/j.coph.2014.04.002. Epub 2014 May 14.

Abstract

G protein-coupled receptors (GPCRs), in recent years, have been shown to signal via multiple distinct pathways. Furthermore, biased ligands for some receptors can differentially stimulate or inhibit these pathways versus unbiased endogenous ligands or drugs. Biased ligands can be used to gain a deeper understanding of the molecular targets and cellular responses associated with a GPCR, and may be developed into therapeutics with improved efficacy, safety and/or tolerability. Here we review examples and approaches to pathway validation that establish the relevance and therapeutic potential of distinct pathways that can be selectively activated or blocked by biased ligands.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Discovery
  • Humans
  • Ligands
  • Receptors, G-Protein-Coupled / metabolism*

Substances

  • Ligands
  • Receptors, G-Protein-Coupled